Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by toinv261on Mar 08, 2017 6:38pm

177 Views

Post# 25954068

Question for fun

In terms of the next licensing deal who would people like to see this deal with?

Would it be a BP?
What about AZ? (Crestor)
What about a new regional deal?
Hepalink owns a bio firm in the USA. Therefore what about USA access for Hepalink?
Possibly CV Venture and the rights to the EU through Boeringer Englehart?
Etc.

Hopefully this will stimulate a little fun and some good thinking about where we are headed.

Cheers
Toinv

Bullboard Posts

Changing Europe’s dependency on HREE from China